Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range.

NYSE:PFE · Pharmaceuticals
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains.
18 October 2025
···

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81stockanalysis.comstockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47%ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same periodts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects mounting investor enthusiasm driven by a confluence of positive news. “Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects,” TechStock² noted in an analysists2.tech.
18 October 2025
···
XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

Shares of XORTX Therapeutics Inc. surged on October 17, 2025 after the nano-cap biotech announced a strategic acquisition in its core therapeutic area. The stock rocketed up immediately following the morning press release, spiking up to 40% in early trading. By midday, XRTX was changing hands at just over $1.20 per shareragingbull.com. It eventually closed about 21% higher on Fridaytipranks.com – a dramatic move for a company that had been trading quietly near the $1 level.
17 October 2025
·
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for too long. Hers was built to serve every woman on her terms,” said Dr. Jessica Shepherd, Chief Medical Officer of Hims & Hers businesswire.com businesswire.com. She noted that the goal is “building a platform that women can trust to access the care they need,” by increasing access to specialists for every life stage businesswire.com.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum bid price, easing near-term delisting fears.
17 October 2025
···

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example, one study in late September suggested GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk, adding to the buzz around Lilly’s pipelinets2.tech.
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levelsreuters.comreuters.com and miles below the late-2024 peakreuters.comreuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion to nearly $4 billion overnight. The explosive rally continued into Friday, Oct. 17: shares gained another ~5% in post-market and pre-market trading stocktwits.com as Wall Street’s reaction grew increasingly bullish.
17 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Pills and a daily pill organizer: Arbli’s liquid formulation helps patients who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly 95 cents” on the newsragingbull.com. By mid-day, Reuters reported SCNX trading near $0.71, up ~30% from the prior closereuters.com.
16 October 2025
··
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded ts2.tech. Market observers noted Adaptimmune as one of the top gainers that session despite the lack of fundamental news nasdaq.com ts2.tech. The rally appeared driven by renewed investor interest and speculation, not new data – a Nasdaq report bluntly stated “no company-specific news was released on September 19” to explain the surge nasdaq.com. Instead, retail traders and momentum algorithms seemed to pile in, possibly in a short-squeeze frenzy or simple fear of missing out.
16 October 2025
··
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would connect women with personalized hormone therapies to ease symptoms like hot flashes and sleep issuests2.tech. This push into a historically underserved sector met eager investor demand. As Benzinga and TS2.tech reported, HIMS stock raced +10–13% that day, trading near $60 with extremely heavy volumets2.tech. By the close, HIMS was up roughly +16%, a one-day gain not seen in monthsts2.techts2.tech.
16 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie’s stock closed at $230.88 on Oct. 10, 2025marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied after Pfizer announced a U.S. drug-pricing dealreuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals remain bullish, and the stock trades above bothmarketbeat.com, though momentum indicators suggest it could be oversold.
11 October 2025
··
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso, Lynparza, Farxiga, and Symbicortmarketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030 with at least 20 new drugs launchedastrazeneca.comastrazeneca.com. Current Chair Michel Demaré and CEO Sir Pascal Soriot lead a company with roughly 70–80,000 employees worldwide, strategic R&D hubs in the US, UK, Sweden, China and emerging cell/gene therapy centers.
11 October 2025
···
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck & Co. is a global healthcare company organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease, cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in H1 2025nasdaq.com. Other pillars include GARDASIL® and type-2 diabetes drugs. Merck invests heavily in R&D, with hundreds of projects in clinical development. In mid-2025 the company announced a transformation plan to reallocate resources toward “new growth drivers” – including acquisitions and upcoming product launches – to drive long-term innovationmerck.com.
11 October 2025
··
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate.
11 October 2025
·····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approvedreuters.com. By then, the landscape may include other new NASH therapies, but Novo’s combination strategy could set it apart. Wolfe Research analyst Andy Chen recently said the field has reached a “meaningful tipping point” as the first therapies emerge, predicting the leading NASH drug could see $5 billion+ in annual sales under broad useinvesting.com. Novo’s own management clearly shares that optimism – they characterize EFX as a potential “first- and best-in-class” treatment for mid-to-late-stage fatty liver diseasebiospace.com. In the near term, investors seem cautiously optimistic: Novo’s stock has soared in 2025 thanks to obesity drug success, and adding Akero is seen as a bold but logical extension of that success into fatty liver disease. “This acquisition embodies Novo Nordisk’s relentless ambition to move faster, go further,” CEO Doustdar proclaimedbiospace.com. If efruxifermin fulfills its promise, Novo could not only help millions of patients with a previously untreatable condition, but also secure a new multi-billion dollar franchise – solidifying its position as a powerhouse in
9 October 2025
··
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan for Acurx’s lead drug, ibezapolstat, in Clostridioides difficile infectioninvesting.com. This essentially means European regulators agree with Acurx’s plan to study ibezapolstat in children, a prerequisite for future marketing approval in Europe. As the company noted, the PIP approval “ensur[es] necessary data are obtained to support the drug’s authorization and use in pediatric populations.”investing.com This news helped lift ACXP stock from about $4.18 to $4.60 at the end of that weeknasdaq.com, reflecting investor optimism about Acurx’s regulatory momentum.
8 October 2025
·
Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

For much of the late 20th century, Puerto Rico was an unlikely but critical component of America’s medicine chest. The island’s status as a U.S. territory provided access to federal intellectual‑property protections, Food and Drug Administration oversight and the “Made in USA” label—all while offering costs and tax advantages more akin to an emerging market. The most potent driver was Section 936, enacted in 1976, which exempted profits earned by U.S. corporations in Puerto Rico from federal income taxes. Pharmaceutical giants set up dozens of plants, creating tens of thousands of jobs and spurring spin‑off industries in packaging, logistics and medical devices. According to Steve Forbes, Section 936 attracted companies and fueled innovation and prosperity, enabling Puerto Rico to produce a significant share of America’s most essential medicinesforbes.com.
6 October 2025
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return ytdreturn.com. Zacks similarly reported a 217.8 % YTD rally by late September nasdaq.com, reflecting further gains in October. The stock traded between US$10.14 and US$106.63 over the past year stockanalysis.com and surged 695.5 % year‑on‑year nasdaq.com.
4 October 2025
··
1 … 46 47 48 49
Follow on Google News
Add as preferred source Open in Google News